Literature DB >> 15073250

Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.

Heiko Schöder1, Yusuf E Erdi, Kenneth Chao, Mithat Gonen, Steven M Larson, Henry W D Yeung.   

Abstract

UNLABELLED: The standardized uptake value (SUV) is the most commonly used parameter to quantify the intensity of radiotracer uptake in tumors. Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed.
METHODS: Phantom studies were performed and clinical whole-body (18)F-FDG PET images of 85 cancer patients were analyzed. All images were reconstructed using either filtered backprojection (FBP) with measured attenuation correction (MAC) or iterative reconstruction (IR) with segmented attenuation correction (SAC). In a subset of 15 patients, images were reconstructed using all 4 combinations of IR+SAC, IR+MAC, FBP+SAC, and FBP+MAC. For phantom studies, a sphere containing (18)F-FDG was placed in a water-filled cylinder and the activity concentration of that sphere was measured in FBP and IR reconstructed images using all 4 combinations. Clinical studies were displayed simultaneously and identical regions of interest (ROIs, 50 pixels) were placed in liver, urinary bladder, and tumor tissue in both image sets. SUV max (maximal counts per pixel in ROI) and SUV avg (average counts per pixel) were measured.
RESULTS: In phantom studies, measurements from FBP images underestimated the true activity concentration to a greater degree than those from IR images (20% vs. 5% underestimation). In patient studies, SUV derived from FBP images were consistently lower than those from IR images in both normal and tumor tissue: Tumor SUV max with IR+SAC was 9.6 +/- 4.5, with IR+MAC it was 7.7 +/- 3.5, with FBP+MAC it was 6.9 +/- 3.0, and with FBP+SAC it was 8.6 +/- 4.1 (all P < 0.01 vs. IR+SAC). Compared with IR+SAC, SUV from FBP+MAC images were 25%-30% lower. Similar discrepancies were noted for liver and bladder. Discrepancies between measurements became more apparent with increasing (18)F-FDG concentration in tissue.
CONCLUSION: SUV measurements in whole-body PET studies are affected by the applied methods for both image reconstruction and attenuation correction. This should be considered when serial PET studies are done in cancer patients. Moreover, if SUV is used for tissue characterization, different cutoff values should be applied, depending on the chosen method for image reconstruction and attenuation correction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073250

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  Segmental acquisition method for stationary objects in (18)F-fluorodeoxyglucose positron emission tomography tests.

Authors:  Keisuke Tsuda; Naoyuki Aikawa; Takayuki Suzuki; Etsuo Moriya; Masayuki Yamaguchi; Hideaki Kitamura; Kouzou Hanai; Izumi O Umeda; Masahiro Fukushi; Noriyuki Moriyama; Hirofumi Fujii
Journal:  Jpn J Radiol       Date:  2010-10-24       Impact factor: 2.374

2.  Consistency Driven Respiratory Phase Alignment and Motion Compensation in PET/CT.

Authors:  Adam Alessio; Steve Kohlmyer; Paul Kinahan
Journal:  IEEE Nucl Sci Symp Conf Rec (1997)       Date:  2007

3.  Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET.

Authors:  M Souvatzoglou; S I Ziegler; M J Martinez; R Busch; G Dzewas; M Schwaiger; F Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-05       Impact factor: 9.236

4.  Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy.

Authors:  Wouter V Vogel; Bart M Wensing; Jorn A van Dalen; Paul F M Krabbe; Frank J A van den Hoogen; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-16       Impact factor: 9.236

5.  A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.

Authors:  Andrea Schaefer; Stephanie Kremp; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch; Ursula Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

6.  Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Authors:  Walter Jentzen; Reiner Weise; Jürgen Kupferschläger; Lutz Freudenberg; Wolfgang Brandau; Ronald Bares; Wolfgang Burchert; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

7.  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).

Authors:  A Noy; H Schöder; M Gönen; M Weissler; K Ertelt; C Cohler; C Portlock; P Hamlin; H W D Yeung
Journal:  Ann Oncol       Date:  2009-01-12       Impact factor: 32.976

8.  Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.

Authors:  Kotaro Higashi; Tsutomu Sakuma; Kengo Ito; Seiji Niho; Yoshimichi Ueda; Takeshi Kobayashi; Ryuzo Sekiguchi; Tomoko Takahashi; Takashi Kato; Hisao Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

9.  Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.

Authors:  M Souvatzoglou; A L Grosu; B Röper; B J Krause; R Beck; G Reischl; M Picchio; H-J Machulla; H-J Wester; M Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-20       Impact factor: 9.236

10.  Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.

Authors:  Masaya Iwamuro; Hiroyuki Okada; Katsuyoshi Takata; Katsuji Shinagawa; Shigeatsu Fujiki; Junji Shiode; Atsushi Imagawa; Masashi Araki; Toshiaki Morito; Mamoru Nishimura; Motowo Mizuno; Tomoki Inaba; Seiyu Suzuki; Yoshinari Kawai; Tadashi Yoshino; Yoshiro Kawahara; Akinobu Takaki; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.